Strides Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE939A01011
  • NSEID: STAR
  • BSEID: 532531
INR
873.00
37.4 (4.48%)
BSENSE

Feb 03

BSE+NSE Vol: 5.64 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationNine Monthly Results
Results Snapshot
Figures in Cr
Consolidate Nine Monthly Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Net Sales
3,535.22
3,374.95
2,935.19
2,702.02
2,204.23
2,407.38
2,133.33
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
3,535.22
3,374.95
2,935.19
2,702.02
2,204.23
2,407.38
2,133.33
Raw Material Cost
1,150.05
1,206.16
904.51
1,173.28
921.75
987.66
844.69
Purchase of Finished goods
234.09
456.48
295.94
119.28
198.71
180.32
110.60
(Increase) / Decrease In Stocks
38.36
-181.65
71.34
-66.37
-45.62
-206.70
-79.46
Employee Cost
681.84
639.89
547.88
556.36
489.65
396.45
318.47
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
-0.02
0.01
-0.01
0.00
0.00
0.00
-0.01
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Expenses
745.31
669.11
653.83
644.85
702.01
572.05
488.18
Total Expenditure (Excl Depreciation)
2,849.63
2,790.00
2,473.49
2,427.40
2,266.50
1,929.78
1,682.47
Operating Profit (PBDIT) excl Other Income
685.59
584.95
461.70
274.62
-62.27
477.60
450.86
Other Income
142.58
46.75
53.24
63.21
45.93
38.38
35.46
Operating Profit (PBDIT)
828.17
631.70
514.94
337.83
-16.34
515.98
486.32
Interest
136.97
198.53
224.72
180.62
127.26
108.46
115.39
Exceptional Items
-20.44
3,280.19
-120.15
8.88
-166.88
44.28
92.42
Gross Profit (PBDT)
670.76
525.25
109.24
147.52
-310.48
451.80
463.35
Depreciation
149.15
143.40
169.14
182.32
172.34
154.43
128.36
Profit Before Tax
521.59
382.79
-72.42
-178.27
-482.82
297.37
334.99
Tax
75.39
56.76
17.99
-62.39
-46.78
20.16
21.80
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
446.22
325.08
-77.86
27.57
-436.03
277.22
313.19
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
3,188.11
60.83
18.57
0.00
14.77
-13.59
Net Profit
446.22
3,513.18
-17.03
46.14
-436.03
291.99
299.60
Share in Profit of Associates
-0.98
-1.29
-87.73
-244.68
-67.18
-78.00
-62.45
Minority Interest
-3.96
3.55
24.75
1.28
3.80
2.99
0.04
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
429.25
3,511.27
-88.79
-193.10
-489.43
222.36
240.31
Equity Capital
92.17
92.16
91.89
90.29
89.78
89.63
89.55
Face Value
10.0
10.0
10.0
10.0
10.0
10.0
10.0
Reserves
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Diluted Earnings per share
21.92
9.55
5.42
-8.86
-13.55
4.22
10.48
Operating Profit Margin (Excl OI)
19.39%
17.33%
15.73%
10.16%
-2.83%
19.84%
21.13%
Gross Profit Margin
18.97%
15.56%
3.72%
5.46%
-14.09%
18.77%
21.72%
PAT Margin
12.62%
9.63%
-2.65%
1.02%
-19.78%
11.52%
14.68%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Nine Monthly Analysis Highlights
stock-summary

Net Sales

YoY Growth in nine months ended Dec 2025 is 4.75% vs 14.98% in Dec 2024

stock-summary

Consolidate Net Profit

YoY Growth in nine months ended Dec 2025 is -87.78% vs 4,054.58% in Dec 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in nine months ended Dec 2025 is 17.20% vs 26.69% in Dec 2024

stock-summary

Interest

YoY Growth in nine months ended Dec 2025 is -31.01% vs -11.65% in Dec 2024

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in nine months ended Dec 2025 has improved from Dec 2024

Compare Nine Monthly Results Of Strides Pharma With
Markets Mojo
Figures in Cr
Consolidate Nine Monthly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
3,535.22
0
3,535.22
Other Operating Income
0.00
0.00
0.00
Total Operating income
3,535.22
0
3,535.22
Raw Material Cost
1,150.05
0
1,150.05
Purchase of Finished goods
234.09
0
234.09
(Increase) / Decrease In Stocks
38.36
0
38.36
Employee Cost
681.84
0
681.84
Power Cost
0.00
0
0.00
Manufacturing Expenses
-0.02
0
-0.02
Selling and Distribution Expenses
0.00
0
0.00
Other Expenses
745.31
0.00
745.31
Total Expenditure (Excl Depreciation)
2,849.63
0
2,849.63
Operating Profit (PBDIT) excl Other Income
685.59
0.00
685.59
Other Income
142.58
0
142.58
Operating Profit (PBDIT)
828.17
0
828.17
Interest
136.97
0
136.97
Exceptional Items
-20.44
0
-20.44
Gross Profit (PBDT)
670.76
0
670.76
Depreciation
149.15
0
149.15
Profit Before Tax
521.59
0
521.59
Tax
75.39
0
75.39
Provisions and contingencies
0.00
0
0.00
Profit After Tax
446.22
0
446.22
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0.00
0
0.00
Other Adjustments
0.00
0
0.00
Net Profit
446.22
0
446.22
Share in Profit of Associates
-0.98
0
-0.98
Minority Interest
-3.96
0
-3.96
Other related items
0.00
0.00
0.00
Consolidated Net Profit
429.25
0
429.25
Equity Capital
92.17
0
92.17
Face Value
10.00
0
0.00
Reserves
0.00
0
0.00
Gross Profit Margin
18.97%
0.00%
0.00
18.97%
PAT Margin
12.62%
0.00%
0.00
12.62%
Public Share Holdings (%)
0.00%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0%
0.00
0.00%
Nine Monthly - Net Sales
Net Sales 3,535.22 Cr
in Dec 2025

Figures in Cr
stock-summary

YoY Growth in nine months ended Dec 2025 is 4.75% vs 14.98% in Dec 2024

Nine Monthly - Consolidate Net Profit
Consolidate Net Profit 429.25 Cr
in Dec 2025

Figures in Cr
stock-summary

YoY Growth in nine months ended Dec 2025 is -87.78% vs 4,054.58% in Dec 2024

Nine Monthly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 685.59 Cr
in Dec 2025

Figures in Cr
stock-summary

YoY Growth in nine months ended Dec 2025 is 17.20% vs 26.69% in Dec 2024

Nine Monthly - Interest
Interest 136.97 Cr
in Dec 2025

Figures in Cr
stock-summary

YoY Growth in nine months ended Dec 2025 is -31.01% vs -11.65% in Dec 2024

Nine Monthly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 19.39%
in Dec 2025

Figures in %
stock-summary

YoY Growth in nine months ended Dec 2025 has improved from Dec 2024